Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Research & Development (2019 - 2025)

Historic Research & Development for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to $2.9 million.

  • Benitec Biopharma's Research & Development fell 1836.56% to $2.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.3 million, marking a year-over-year increase of 1744.51%. This contributed to the annual value of $18.3 million for FY2025, which is 1744.51% up from last year.
  • Latest data reveals that Benitec Biopharma reported Research & Development of $2.9 million as of Q2 2025, which was down 1836.56% from $6.5 million recorded in Q1 2025.
  • Benitec Biopharma's Research & Development's 5-year high stood at $6.5 million during Q1 2025, with a 5-year trough of $2.2 million in Q1 2022.
  • Over the past 5 years, Benitec Biopharma's median Research & Development value was $3.2 million (recorded in 2022), while the average stood at $3.5 million.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 25917.31% in 2021, then crashed by 2128.35% in 2022.
  • Over the past 5 years, Benitec Biopharma's Research & Development (Quarter) stood at $3.1 million in 2021, then grew by 19.55% to $3.8 million in 2022, then soared by 35.66% to $5.1 million in 2023, then grew by 5.55% to $5.4 million in 2024, then plummeted by 46.76% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q2 2025, $6.5 million for Q1 2025, and $5.4 million during Q4 2024.